|
1
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu QF, Liu C, Tai MH, et al: Knockdown of
FoxM1 by siRNA interference decreases cell proliferation, induces
cell cycle arrest and inhibits cell invasion in MHCC-97H cells in
vitro. Acta Pharmacol Sin. 31:361–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahmad A, Wang Z, Kong D, et al: FoxM1
down-regulation leads to inhibition of proliferation, migration and
invasion of breast cancer cells through the modulation of
extra-cellular matrix degrading factors. Breast Cancer Res Treat.
122:337–346. 2010. View Article : Google Scholar
|
|
4
|
Nakamura S, Hirano I, Okinaka K, et al:
The FOXM1 transcriptional factor promotes the proliferation of
leukemia cells through modulation of cell cycle progression in
acute myeloid leukemia. Carcinogenesis. 31:2012–2021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: a representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar
|
|
6
|
Green AS, Chapuis N, Lacombe C, Mayeux P,
Bouscary D and Tamburini J: LKB1/AMPK/mTOR signaling pathway in
hematological malignancies: from metabolism to cancer cell biology.
Cell Cycle. 10:2115–2120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spender LC and Inman GJ: Phosphoinositide
3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt’s
lymphoma cells to BH3 mimetics. Mol Cancer Res. 10:347–359.
2012.PubMed/NCBI
|
|
8
|
Feng Y, Ke C, Tang Q, et al: Metformin
promotes autophagy and apoptosis in esophageal squamous cell
carcinoma by downregulating Stat3 signaling. Cell Death Dis.
5:e10882014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Warren M, Luthra R, Yin CC, et al:
Clinical impact of change of FLT3 mutation status in acute myeloid
leukemia patients. Mod Pathol. 25:1405–1412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wonsey DR and Follettie MT: Loss of the
forkhead transcription factor FoxM1 causes centrosome amplification
and mitotic catastrophe. Cancer Res. 65:5181–5189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhat UG, Halasi M and Gartel AL: Thiazole
antibiotics target FoxM1 and induce apoptosis in human cancer
cells. PLoS One. 4:e55922009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kiyoi H, Yanada M and Ozekia K: Clinical
significance of FLT3 in leukemia. Int J Hematol. 82:85–92. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yanada M, Matsuo K, Suzuki T, Kiyoi H and
Naoe T: Prognostic significance of FLT3 internal tandem duplication
and tyrosine kinase domain mutations for acute myeloid leukemia: a
meta-analysis. Leukemia. 19:1345–1349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frohling S, Schlenk RF, Breitruck J, et
al: Prognostic significance of activating FLT3 mutations in younger
adults (16 to 60 years) with acute myeloid leukemia and normal
cytogenetics: a study of the AML Study Group Ulm. Blood.
100:4372–4380. 2002.
|
|
16
|
Green AS, Chapuis N, Maciel TT, et al: The
LKB1/AMPK signaling pathway has tumor suppressor activity in acute
myeloid leukemia through the repression of mTOR-dependent oncogenic
mRNA translation. Blood. 116:4262–4273. 2010. View Article : Google Scholar
|
|
17
|
Memmott RM, Mercado JR, Maier CR, Kawabata
S, Fox SD and Dennis PA: Metformin prevents tobacco carcinogen -
induced lung tumorigenesis. Cancer Prev Res (Phila). 3:1066–1076.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oliveras-Ferraros C, Cufi S,
Vazquez-Martin A, et al: Micro(mi)RNA expression profile of breast
cancer epithelial cells treated with the anti-diabetic drug
metformin: induction of the tumor suppressor miRNA let-7a and
suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle.
10:1144–1151. 2011.
|
|
19
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar
|
|
20
|
Wang X, Hung NJ and Costa RH: Earlier
expression of the transcription factor HFH-11B diminishes induction
of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry
into S-phase following carbon tetrachloride liver injury.
Hepatology. 33:1404–1414. 2001. View Article : Google Scholar
|
|
21
|
Wang X, Krupczak-Hollis K, Tan Y,
Dennewitz MB, Adami GR and Costa RH: Increased hepatic Forkhead Box
M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration
through diminished p27Kip1 protein levels and increased Cdc25B
expression. J Biol Chem. 277:44310–44316. 2002. View Article : Google Scholar
|
|
22
|
Sun DF, Zhang YJ, Tian XQ, Chen YX and
Fang JY: Inhibition of mTOR signalling potentiates the effects of
trichostatin A in human gastric cancer cell lines by promoting
histone acetylation. Cell Biol Int. 38:50–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
MacKenzie MJ, Ernst S, Johnson C and
Winquist E: A phase I study of temsirolimus and metformin in
advanced solid tumours. Invest New Drugs. 30:647–652. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin-Castillo B, Dorca J, Vazquez-Martin
A, et al: Incorporating the antidiabetic drug metformin in
HER2-positive breast cancer treated with neo-adjuvant chemotherapy
and trastuzumab: an ongoing clinical-translational research
experience at the Catalan Institute of Oncology. Ann Oncol.
21:187–189. 2010. View Article : Google Scholar
|
